Clinical use of meronem on adult mucoviscidotic patients

Abstract

Meronem (Zeneca Co.), a new Carbapenem antibiotic, was used for monotherapy of adults affected with mucoviscidosis. This antibacterial therapy was evaluated on the following criteria: the dynamics of clinical manifestations on the Schwachmann scale; X-ray studies of thoracic organs in their dynamics; and determination of the external respiratory function with the use of general bodyplethysmography and bacteriological studies of mucus. Meronem # sensitivity was measured by agar diffusion with standard disks provided by the Zeneca.
Meronem was administered in intravenous infusions at 60 mg/kg of body weight every 24 hrs during 10 days. 'Positive clinical effects were observed with 3 patients. One achieved clinical stability. We attained bacteriological confirm ation of a spectacular titer reduction to occasional colonies: Ps.aeruginosa with 2 patients, and Ps.aeruginosa mucosa with 3 women patients. The doses we were using revealed good tolerance and an absence of side effects. The studies showed Meronem monotherapy at a daily 60 m g/kg to be effective and recommendable for adult m ucoviscidotic patients.